Nicox S.a.

Merck Sharp + Dohme Corp.

Nicox Science Ireland

Schering Corporation

Nicox

Ferrer Internacional, S.a.

Ennio Ongini

Piero Del Soldato

Francesca Benedini

Nicoletta Almirante

Stefano Biondi

Valerio Chiroli

Laura Storoni

Amjad Ali

Michael Man-Chu Lo

Silvia Stefanini

Iyassu Sebhat

Christopher L Franklin

Annalisa Bonfanti

Rebecca Steele

Pier Giovanni Baraldi

Giancarlo Santus

Antonio Guglietta

Wesley Kwan Mung Chong

Giulio Cossu

Silvia Brunelli

Emilio Clementi

Elena Bastia

Francesco Impagnatiello

Michael Niesman

Chris Franklin

Massimiliano Ferrario

Achim Hans-Peter Krauss

Alessia Nicotra

Marta Princep

Piero Del Soldata

Silvio Dionisotti

Monica Valeria Viziano

Barbara Cacciari

Daniela Miglietta

Daniel Palop

The present invention relates to compositions comprising a 4-nitrooxybutan-1-ol alkyl ester as nitric oxide donor. More specifically, the invention relates to compositions comprising 4-nitrooxybutan-1-ol alkyl ester as a nitric oxide donor and an ophthalmic drug, useful in controlling elevated intraocular pressure associated with glaucoma or ocular hypertension associated with other diseases or conditions. The invention is also directed to methods of controlling intraocular pressure utilizing said compositions.

Ophthalmic compositions containing a nitric oxide donor

The present invention relates to novel nitric oxide donor compounds for the use in the treatment and/or prophylaxis of hypertensive glaucoma, normotensive glaucoma and ocular hypertension.

Quinone based nitric oxide donating compounds for ophthalmic use

The invention relates to nitric oxide donor compounds and their use for treating cardiovascular diseases, inflammation, pain, fever, gastrointestinal disorders, ophthalmic diseases, hepatic disorders, renal diseases, respiratory disorders, immunological diseases, bone metabolisms dysfunctions, central and peripheral nervous system diseases, sexual dysfunctions, infectious diseases, for the inhibition of platelet aggregation and platelet adhesion, for treating pathological conditions resulting from abnormal cell proliferation, vascular diseases. The invention also relates to compositions comprising at least one nitric oxide releasing compounds of the invention and composition comprising at least one nitric oxide releasing compounds according to the invention and at least one 15 therapeutic agent.

Nitric oxide donor compounds

The invention relates to nitrooxy derivatives of fluocinolone acetonide, triamcinolone acetonide, betamethasone and beclomethasone, methods for their preparation, pharmaceutical compositions containing these compounds, and methods of using these compounds and compositions for treating diabetic macular edema, diabetic retinopathy, macular degeneration, age-related macular degeneration and other diseases of retina and macula lutea.

Glucocorticoids attached to nitrate esters via an aromatic linker in position 21 and their use in ophthalmology

The invention relates to nitrooxyderivative of corticosteroids of general formula (I) and pharmaceutically acceptable salts or stereoisomers thereofR&#x2014;(Z)&#x2014;R&#x2003;&#x2003;(I)wherein R is the corticosteroid residue of formula (II): wherein:  The compounds are useful in the treatment of respiratory diseases, inflammatory diseases, dermatological diseases and ocular diseases.

Nitric oxide releasing steroids

The present invention relates to the use of nitric oxide releasing compounds for retarding or reversing muscular dystrophies such as Duchenne and Becker dystrophies.

Use of nitrooxyderivative of drug for the treatment of muscular dystrophies

Use of nitrooxyderivatives of drug for the treatment of muscular dystrophies

A compound having the structure wherein R is, for example, Y is selected from the group consisting of 1) R5, 2) &#x2014;C(R1R2) (C(R3R4))0-1Y1R5, and 3) &#x2014;C(R1R2)&#x2014;O&#x2014;Y1R5; R1, R2, R3 and R4 are independently selected from the group consisting of hydrogen and C1-4 alkyl; R5 is; Y1 is selected from the group consisting of C(O)&#x2014;O&#x2014; and P(O)(OR6)&#x2014;O&#x2014;; and R6 is hydrogen or CH3, or a pharmaceutically acceptable salt thereof, and methods of using the compounds for treating hypertension. 

Angiotensin II receptor antagonists

A compound having the structure wherein R is an angiotensin receptor antagonist active group, and Y is provided that when Y is &#x2014;C(O)(CH)R, then R is 

A compound having the structureR&#x2014;Y  

Prostaglandin nitroderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.

Prostaglandin derivatives

The present invention relates to nitrooxyderivatives or salts thereof having the following general formula (I):R&#x2014;NR&#x2014;(K)&#x2014;(B)&#x2014;(C)&#x2014;NO&#x2003;&#x2003;(I)whereinc0, b0 and k0 are 0 or 1;R is the radical of an analgesic drug for chronic pain, for instance neurophatic pain;Ris H or alkyl with from 1 to 5 carbon atoms;B is such that its precursor is selected from amino acids, hydroxy acids, polyalcohol, compounds;C is a bivalent radical containing an aliphatic, heterocyclic or aromatic radical.

Drugs for chronic pain

The present invention relates to &#x3b2;-adrenergic blockers nitrooxyderivatives of general formula (I):A-(Y&#x2014;ONO)and enantiomers and diastereoisomers and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them and their use for the treatment of hypertension, cardiovascular diseases, glaucoma, migraine headache and vascular diseases.

Nitrooxyderivatives of carvedilol and other beta blockers as antihypertensive

Growing community of inventors

Segrate, Italy

Ennio Ongini